ATAI:NASDAQ
AtaiBeckley Inc
US$4.20
arrow_upward
+1.57%(+0.065) 1 天
US$4.26
arrow_upward
+1.43% (+0.060)bedtime盘后交易
休市： 5月4日, GMT-4 16:00:01 · USD
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 ATAI 生成关键数据洞见…
开盘价
US$4.11
最高价
US$4.28
最低价
US$4.04
市值
一五.四一亿
平均成交量
六五八.六六万
成交量
六九八.五七万
52 周最高价
US$6.72
52 周最低价
US$1.29
每股收益
-US$2.91
Beta 版
一.五九
流通股数
三.六七亿
员工人数
九九
新闻报道
来自全网
资料
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
AtaiBeckley Inc简介